WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Thank you for another great WorkBoat Show! We hope to see everyone back in New Orleans December 2–4, 2026. Save the date!

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.53 -0.05 (-0.10%)
Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
From Genentech
Via Business Wire
News headline image
Genentech Announces Agreement With U.S. Government
From Genentech
Via Business Wire
News headline image
Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
From Genentech
Via Business Wire
News headline image
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
From Genentech
Via Business Wire
News headline image
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
From Genentech
Via Business Wire
News headline image
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
From Genentech
Via Business Wire
News headline image
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
From Genentech
Via Business Wire
News headline image
Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
From Genentech
Via Business Wire
News headline image
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
From Genentech
Via Business Wire
News headline image
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
From Genentech
Via Business Wire
News headline image
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
From Genentech
Via Business Wire
News headline image
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
News headline image
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
From Genentech
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
From Genentech
Via Business Wire
News headline image
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
From Genentech
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
From Genentech
Via Business Wire
News headline image
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
From Genentech
Via Business Wire
News headline image
Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer
From Genentech
Via Business Wire
News headline image
New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
News headline image
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
From Genentech
Via Business Wire
News headline image
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
From Genentech
Via Business Wire
News headline image
Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
News headline image
Genentech and Roche Present New Insights in Alzheimer’s Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
From Genentech
Via Business Wire
News headline image
Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease
From Genentech
Via Business Wire
News headline image
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
News headline image
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
From Genentech
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2025 Diversified Communications. All rights reserved.